<DOC>
	<DOCNO>NCT00580190</DOCNO>
	<brief_summary>PF-00572778 , CRH antagonist , expect attenuate adrenocorticotropin ( ACTH ) cortisol responses naloxone block effect CRH increase induced naloxone postsynaptic receptor . Demonstration statistically significant attenuation naloxone induce increase cortisol and/or ACTH concentration PF-00572778 compare placebo would thus constitute proof mechanism compound . Therefore , study evaluate pharmacodynamic effect PF-00572778 follow naloxone challenge healthy subject .</brief_summary>
	<brief_title>Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alprazolam</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Healthy male and/or female subject age 18 45 year ; Body Mass Index ( BMI ) approximately 18 30 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ; Family ( 1st degree relative ) personal history meeting Diagnostic Statistical Manual IV ( DSMIV ) criteria alcohol abuse dependence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>